191
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1483L |
Abl Cytosolic Substrate acetate
Abl Cytosolic Substrate acetate(168202-46-8 free base) |
Others | Others |
Abl Cytosolic Substrate acetate(168202-46-8 free base) 是 Abelson 酪氨酸激酶 (Abl) 的底物。 | |||
T10800 |
CHMFL-ABL-121
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
CHMFL-ABL-121 是一种 II 型 ABL 激酶高效抑制剂,抑制纯化的非活性 ABL wt 和 T315I 激酶蛋白的 IC50 值分别为 2 nM 和 0.2 nM。 | |||
T10799 |
CHMFL-ABL-039
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
CHMFL-ABL-039 是一种具有高效选择性的 Ⅱ 型野生型 ABL 激酶和耐药 V299L 突变型 BCR-ABL 激酶的抑制剂,IC50 分别为 7.9 nM、27.9 nM。CHMFL-ABL-039 可用于慢性粒细胞白血病 (CML) 的研究。 | |||
T10801 |
CHMFL-ABL/KIT-155
CHMFL-ABL-KIT-155 |
c-Kit | Tyrosine Kinase/Adaptors |
CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM). It arrests cell cycle progression and induces apoptosis. | |||
T18595 |
Dasatinib carbaldehyde
PROTAC ABL binding moiety 4,BMS-354825 carbaldehyde |
Others; Ligands for Target Protein for PROTAC | Others; PROTAC |
Dasatinib carbaldehyde (PROTAC ABL binding moiety 4) 基于 ABL 抑制剂达沙替尼,通过接头与 IAP 配体结合,形成 SNIPER [1]。 | |||
T72958 |
BCR-ABL-IN-7
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
BCR-ABL-IN-7 是一种 WT 和 T315I 突变体 ABL 激酶抑制剂。BCR-ABL-IN-7 有效抑制 WT 和 T315I 突变体 ABL 激酶的活性。BCR-ABL-IN-7 可以用于慢性髓系白血病 (CML) 的研究。 | |||
T18685 | SNIPER(ABL)-015 | Others | Others |
SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5 μM [1]. | |||
T18687 |
SNIPER(ABL)-020
|
Others | Others |
SNIPER(ABL)-020 is a chemical compound consisting of Dasatinib, an ABL inhibitor, and Bestatin, an IAP ligand, conjugated with a linker. This compound effectively reduces the BCR-ABL protein[1]. | |||
T34670 |
SNIPER(ABL)-38
|
||
SNIPER(ABL)-38 is a specific and nongenetic IAP-dependent protein eraser (SNIPER) which acts as a protein degradation inducer of oncogenic BCR-ABL protein. | |||
T18693 |
SNIPER(ABL)-049
|
Others | Others |
SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 100 μM[1]. | |||
T18691 |
SNIPER(ABL)-044
|
Others | Others |
SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM[1]. | |||
T39732 |
BCR-ABL-IN-3
|
||
BCR-ABL-IN-3 is a highly effective and irreversibly binding inhibitor of Bcr-Abl, displaying a remarkable potency with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151. This compound exhibits significant anti-cancer activity. | |||
T39827 | c-ABL-IN-1 | ||
C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's disease. | |||
T18690 |
SNIPER(ABL)-039
|
Others | Others |
SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively[1]. | |||
T18684 | SNIPER(ABL)-013 | Others | Others |
SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 20 μM[1]. | |||
T18686 | SNIPER(ABL)-019 | Others | Others |
SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM[1]. | |||
T18688 |
SNIPER(ABL)-024
|
Others | Others |
SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5μM[1]. | |||
T18694 |
SNIPER(ABL)-050
|
Others | Others |
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker. This conjugation results in the reduction of BCR-ABL protein[1]. | |||
T18689 | SNIPER(ABL)-033 | Others | Others |
SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM[1]. | |||
T18695 | SNIPER(ABL)-058 | Others | Others |
SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM[1]. | |||
T18692 |
SNIPER(ABL)-047
|
Others | Others |
SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 2 μM[1]. | |||
T22067 |
CHMFL-ABL-053
|
||
CHMFL-ABL-053 (Compound 18a) 是一种有效的、选择性的、具有口服活性的 BCR-ABL、SRC 和 p38激酶抑制剂,IC50值分别为 70、90 和 62 nM。CHMFL-ABL-053 是一种潜在有效的慢性粒细胞白血病 (CML) 候选药物 [1]。 | |||
TP1483 |
Abl Cytosolic Substrate
|
||
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). | |||
T18907 |
ABL-001-Amide-PEG3-acid
|
Others | Others |
ABL-001-Amide-PEG3-acid, an analogue to ABL-001, primarily serves as a labeled chemical or fluorescent probe. | |||
T10488 | BCR-ABL-IN-1 | Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia. | |||
T10489 |
BCR-ABL-IN-2
|
Others | Others |
BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I). | |||
T63297 | ABL-L | ||
ABL-L 能够利用 p53 依赖的途径,诱导人喉癌细胞凋亡。 | |||
T5177 |
Asciminib
ABL001 |
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Asciminib (ABL001) 是一种有效的、选择性的变构BCR-ABL1抑制剂,能够抑制 Ba/F3 细胞生长 (IC50:0.25 nM)。 | |||
T18593 |
GNF5-amido-Me
PROTAC ABL binding moiety 2 |
Others | Others |
GNF5-amido-Me, the moiety based on GNF5 (ABL inhibitor),binds through a linker to the IAP ligand forming SNIPER[1]. | |||
T63932 |
BCR-ABL-IN-4
|
||
BCR-ABL-IN-4 是 BCR-ABLL 抑制剂,表现出抗癌活性。BCR-ABL-IN-4 对癌细胞生长具有抑制作用,能够作用于 K562 细胞 (IC50: 0.67 nM) 和 BCR-ABL T315I 转染的 Ba/F3 细胞 (IC50: 16 nM)。 | |||
T61546 |
c-ABL-IN-3
|
||
c-ABL-IN-3, a highly effective c-Abl inhibitor, exhibits promising potential for studying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), as well as cancer [1]. The activation of c-Abl has been strongly implicated in a range of diseases, notably cancer [1]. It offers valuable opportunities for research in these fields [1]. | |||
T63332 |
BCR-ABL-IN-5
|
||
BCR-ABL-IN-5 是一种 Bcr-Abl (Breakpoint cluster region-Abelson) 激酶抑制剂,能够作用于 Bcr-AblWT (IC50: 0.014 μM)和 Bcr-AblT3151 (IC50: 0.45 μM),表现出一定的抗白血病细胞增殖作用。 | |||
T61128 | c-ABL-IN-2 | ||
C-ABL-IN-2 is a highly effective inhibitor of the c-Abl protein, which plays a significant role in the development of several diseases, including cancer. This compound exhibits promise for investigating neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), as well as cancer. (Source: WO2020260871A1, compound 25) [1]. | |||
T18594 |
HG-7-85-01-Decyclopropane
PROTAC ABL binding moiety 3 |
Others | Others |
Decyclopropane, also known as HG-7-85-01, is a chemical compound with ABL inhibitor properties. It binds to the IAP ligand through a linker, resulting in the formation of SNIPER [1]. | |||
T62065 |
c-ABL-IN-4
|
||
c-ABL-IN-4 是有效的c-Abl 抑制剂。 | |||
T83711 |
Abl Substrate Peptide TFA
|
||
Abl底物多肽是酪氨酸激酶Abl的多肽底物。在20 µM浓度下,相较于c-Src激酶,它被Abl选择性磷酸化。Abl底物多肽已被用于体外定量Abl激酶活性。 | |||
T82909 |
BCR-ABL-IN-8
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
BCR-ABL-IN-8(化合物26f)是一种具有三甲氧基基团(trimethoxy group)的BCR-ABL抑制剂。 | |||
T63450 |
BCR-ABL-IN-6
|
||
BCR-ABL-IN-6 (9h) 是一种伊马替尼衍生物,也是 Bcr-Abl 激酶的选择性抑制剂,能够作用于 Bcr-AblWT (IC50: 4.6 nM) 和 Bcr-AblT3151 (IC50: 277 nM)。BCR-ABL-IN-6 (9h)对 Bcr-Abl 激酶具有较强的细胞内亲和力 (EC50: 14.6 nM)。BCR-ABL-IN-6 (9h) 能够用于研究慢性髓细胞性白血病治疗。 | |||
T79716 |
c-ABL-IN-5
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
c-ABL-IN-5是一种选择性c-Abl抑制剂,具有神经保护功能。该化合物显示出血脑屏障渗透性、代谢稳定性和优良的药物动力学特性。经[18F]标记的c-ABL-IN-5(化合物[18F]3)可用作PET示踪剂,以评估疾病改善的功效。此外,c-ABL-IN-5适用于帕金森病(PD)等神经退行性疾病的研究。 | |||
T18592 |
Imatinib carbaldehyde
CGP-57148B carbaldehyde,STI571 carbaldehyde,PROTAC ABL binding moiety 1 |
Others | Others |
Imatinib carbaldehyde (also known as CGP-57148B carbaldehyde) is a compound derived from Imatinib, an inhibitor of the ABL protein. Imatinib carbaldehyde binds to the IAP ligand with the assistance of a linker, resulting in the formation of SNIPER[1]. | |||
T0152 |
Bosutinib
伯舒替尼,SKI-606 |
Bcr-Abl; Src; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Bosutinib (SKI-606) 是一种合成的喹诺酮衍生物和双激酶抑制剂,靶向 Abl 和 Src 激酶的 IC50分别为 1 nM 和 1.2 nM。 | |||
T77974 |
PROTAC BCR-ABL Degrader-1
|
PROTACs | PROTAC |
PROTACBCR-ABLDegrader-1(化合物PROTAC1)是一种含有2-oxoethyl linker的PROTAC。该化合物能通过泛素蛋白酶体(ubiquitinproteasom)系统诱导Bcr-Abl的降解,并对K562细胞表现出抗增殖效果,显示出其在癌症研究中的应用潜力。 | |||
T8488 |
GMB-475
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
GMB-475 是一种基于PROTAC 的BCR-ABL1酪氨酸激酶降解剂,克服了BCR-ABL1依赖的耐药性。 GMB-475 靶向 BCR-ABL1 蛋白并募集 E3 连接酶 Von Hippel Lindau (VHL)。导致泛素化和随后的致癌融合蛋白降解 | |||
T21785 |
AG957
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Tyrphostin AG957 是一种酪氨酸激酶抑制剂,具有抗BCR/ABL 酪氨酸激酶活性。它能够抑制p210bcr/abl 酶活性 (IC50:2.9 μM)。 | |||
T3063 |
PD173955
PD-173955,PD 173955 |
Apoptosis; Bcr-Abl; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PD173955是一种Src 激酶家族选择性抑制剂,对Src、Yes 和Abl 激酶IC50值约为22nM, 对 FGFRα 的效力较低,对InsR 和PKC 无活性。 | |||
T17267 |
XL228
|
IGF-1R; Bcr-Abl; Src; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
XL228 是一种多靶点酪氨酸激酶抑制剂,对 Bcr-Abl、Aurora A、IGF-1R、Src 和 Lyn 的 IC50 分别为 5、3.1、1.6、6.1和 2 nM。 | |||
T6300 |
Degrasyn
WP1130 |
Apoptosis; JAK; Bcr-Abl; DUB; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors; Ubiquitination |
Degrasyn (WP1130) 是一种可渗透细胞的去泛素化酶(DUB)抑制剂,直接抑制USP9x,USP5,USP14和UCH37的DUB 活性。 它减弱抗细胞凋亡蛋白Bcr-Abl 和JAK2。 | |||
T2429 |
Olverembatinib dimesylate
GZD824 Dimesylate,HQP1351 |
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Olverembatinib dimesylate (GZD824 Dimesylate) 是一种高效的、口服具有活性的pan-Bcr-Abl 抑制剂,具有抗肿瘤活性。它能广泛而有效地抑制突变型 Bcr-Abl。它对天然的 Bcr-Abl 和 Bcr-AblT315I 作用的IC50值分别为 0.34 nM 和 0.68 nM。 | |||
T11916 |
Lyn-IN-1
巴非替尼,Bafetinib analog |
Bcr-Abl; Src | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Lyn-IN-1 (Bafetinib analog) 是一种高活性 Bcr-Abl 和 Lyn 双重抑制剂。 | |||
T2372 |
Ponatinib
帕纳替尼,AP24534,普纳替尼 |
VEGFR; FGFR; Bcr-Abl; PDGFR; Src; c-Kit; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Ponatinib (AP24534) 是一种有口服活性的多靶点激酶抑制剂,抑制Abl、PDGFRα、VEGFR2、FGFR1和Src 的IC50分别为 0.37 nM、1.1 nM、1.5 nM、2.2 nM 和 5.4 nM。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3S1553 |
trans-Cinnamaldehyde
Cinnamaldehyde,Cinnamic aldehyde,桂皮醛,反式肉桂醛,Cinnamal,Phenylacrolein |
COX; Endogenous Metabolite | Immunology/Inflammation; Metabolism; Neuroscience |
trans-Cinnamaldehyde (Phenylacrolein) 是一种能够用于合成反式肉桂醛-β-环糊精复合物,一种能够食用的抗菌涂层,能够延长鲜切水果的保质期。它是一种能够通过烷基异氰化物与乙炔二羧酸二烷基酯的反应来合成高度多官能的呋喃环。 |